Browse Studies — Arctuva

Phase 2

A Phase II Study of Ivonescimab as Monotherapy or in Combination With Platinum/Pemetrexed Chemotherapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Harboring Actionable Genomic Alterations (AGAs)

The goal of this clinical trial is to assess the efficacy of ivonescimab monotherapy in patients with advanced non-small cell lung cancer harboring actionable …

Lung Cancer (NSCLC)Lung Cancer Non-Small Cell Cancer (NSCLC)Lung Cancer (Non-Small Cell)+3 more

Estimated

~$10 – $6,250

Massachusetts General HospitalNCT07405190

Phase 2

A Phase 2 Study to Investigate the Safety and Efficacy of Petosemtamab in Adults With Metastatic Non-Small Cell Lung Cancer in Combination With Pembrolizumab as First-Line Treatment

The study will test the efficacy and safety of petosemtamab in combination with Pembrolizumab in first line patients with squamous non-small cell lung cancer a…

Lung Cancer - Non Small Cell SquamousLung Cancer - Non Small Cell Non-Squamous

Estimated

~$10 – $7,500

Merus B.V.NCT07353957

Observational

Exercise and the Lung Cancer Tumor Microenvironment

There is increased interest and knowledge about the lung cancer tumor microenvironment (TME). Investigators hypothesize that patients with better baseline phys…

Lung Cancer - Non Small Cell

Estimated

~$10 – $6,250

University of ArizonaNCT07216209

Utilizing Long-read Sequencing to Investigate the EGFR Landscape of EGFR Positive Lung Cancer Patients

EGFR gene mutations are some of the most commonly occurring mutations in non-small cell lung cancer. Investigators have developed a DNA instability model that …

Lung Cancer - Non Small CellEGFR Exon 19 Deletion Mutation

Estimated

~$10 – $750

Our Lady of the Lake HospitalNCT06659458